•Metastasis modeling |
•PK-PD modeling |
•Incorporation of primary cells |
•Invasion/intravasation |
•Absorption |
•Induced pluripotent stem (iPS) cells |
•Survival/dormaney |
•Distribution |
•Adult tissue resident stem cells |
•Extravasation |
•Metabolism |
•Biopsy-, blood- or tissue-derived cells |
•Metastatic niche |
•Excretion |
•Cancer stem cells |
•Epithelial-mesenchymal transition |
•Toxicity |
•Patient-derived organoids |
•Tumor heterogeneity/evolution |
•High-throughput designs |
•Genetically modified cells |
•Mechanical forces |
•Efficacy testing |
•Integration with Big Data |
•Tumor-ECM interactions |
•Novel compound validation |
‘Omics’ signatures/readouts |
•Tumor-stromal interactions |
•Tumor resistance/sensitivity |
•Genome wide association studies (GWAS) |
•Organ-specific microenvironments |
•Mechanistic studies |
•Computational modeling |
•Immuno-oncology studies |
|
•Biomarker discovery/validation |
•Species-specific models |
|
•Individualized trials-on-chip |
|
|
•Tailored clinical management |